Ionis Pharmaceuticals Inc (NASDAQ: IONS) is -11.72% lower on its value in year-to-date trading and has touched a low of $33.32 and a high of $54.44 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The IONS stock was last observed hovering at around $44.11 in the last trading session, with the day’s gains setting it 0.55%.
Currently trading at $44.66, the stock is 2.20% and -4.92% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.89 million and changing 1.25% at the moment leaves the stock -1.29% off its SMA200. IONS registered 32.44% gain for a year compared to 6-month gain of -3.50%. The firm has a 50-day simple moving average (SMA 50) of $7.15 and a 200-day simple moving average (SMA200) of -$23.88.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -5.80% loss in the last 1 month and extending the period to 3 months gives it a -12.94%, and is 4.39% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 2.53% over the week and 2.61% over the month.
Ionis Pharmaceuticals Inc (IONS) has around 927 employees, a market worth around $6.51B and $788.14M in sales. Profit margin for the company is -46.44%. Distance from 52-week low is 34.03% and -17.97% from its 52-week high. The company has generated returns on investments over the last 12 months (-15.91%).
Ionis Pharmaceuticals Inc quarterly earnings per share for the current quarter are estimated at -$1.04 with sales reaching $144.06M over the same period.The EPS is expected to shrink by -54.01% this year, but quarterly earnings will post -19.60% year-over-year. Quarterly sales are estimated to grow 12.40% in year-over-year returns.
499 institutions hold shares in Ionis Pharmaceuticals Inc (IONS), with institutional investors hold 101.91% of the company’s shares. The shares outstanding are 144.34M, and float is at 133.94M with Short Float at 7.22%. Institutions hold 101.03% of the Float.
The top institutional shareholder in the company is FMR, LLC with over 21.46 million shares valued at $880.66 million. The investor’s holdings represent 15.00% of the IONS Shares outstanding. As of Jun 29, 2023, the second largest holder is Vanguard Group Inc with 14.52 million shares valued at $595.89 million to account for 10.15% of the shares outstanding. The other top investors are T. Rowe Price Investment Management, Inc. which holds 13.08 million shares representing 9.14% and valued at over $536.83 million, while Bellevue Group AG holds 6.56% of the shares totaling 9.38 million with a market value of $384.87 million.
Ionis Pharmaceuticals Inc (IONS) Insider Activity
The most recent transaction is an insider sale by Monia Brett P, the company’s Chief Executive Officer. SEC filings show that Monia Brett P sold 387 shares of the company’s common stock on Feb 16 ’24 at a price of $44.49 per share for a total of $17219.0. Following the sale, the insider now owns 0.17 million shares.
Ionis Pharmaceuticals Inc disclosed in a document filed with the SEC on Feb 02 ’24 that Monia Brett P (Chief Executive Officer) sold a total of 23,501 shares of the company’s common stock. The trade occurred on Feb 02 ’24 and was made at $49.37 per share for $1.16 million. Following the transaction, the insider now directly holds 0.17 million shares of the IONS stock.
Still, SEC filings show that on Feb 02 ’24, Cadoret-Manier Onaiza (EVP, Chf GL Pdt Str & Oper Ofc) disposed off 2,125 shares at an average price of $49.60 for $0.11 million. The insider now directly holds 35,825 shares of Ionis Pharmaceuticals Inc (IONS).
